Stay updated on XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Sign up to get notified when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.

Latest updates to the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page
- Check2 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.2%
- Check17 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while several specific terms related to ovarian cancer and other cancer types have been removed.SummaryDifference2%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to include detailed information about a Phase 1b clinical trial for the drug XMT-1592, which targets ovarian cancer and non-small cell lung cancer. This includes specifics on study design, eligibility criteria, and contact information for participation.SummaryDifference100%
Stay in the know with updates to XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.